参考文献
1.van Doorn PA，Ruts L，Jacobs BC.Clinical features，pathogenesis，and treatment of Guillain-Barrés syndrome.Lancet Neurol，2008，7:930-950.
2.Lunn MP，Willison HJ.Diagnosis and treatment in inflammatory neuropathis.J Neurol Neurosurg Psychistry，2009，80:249-258.
3.中华医学会神经病学分会神经肌肉病学组.中国吉兰巴雷综合征诊治指南.中华神经科杂志，2010，43（8）:583-586.
4.Dalakas MC.The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases:evidence-based indications and safety profile.Pharmacol Ther，2004，102:177-193.
5.Huges RA，Swan AV，Raphael JC，et al.Immunotherapy for Guillain-Barré syndrome:a systematic review.Brain，2007，130:2245-2257.
6.Hiraga A，Mori M，Ogawara K，et al.Recovery patterns and long term prognosis for axonal Guillain-Barrés syndrome.J Neurol Neursurg Psychiatry，2005，76:719-722.
7.van Koningsveld R，Schmitz PI，Meché FG，et al.Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome:randomised trial.Lancet，2004，363（9404）:192-196.(https://www.daowen.com)
8.Walgaard C，Lingsma HF，Ruts L，et al.Prediction of respiratory insufficiency in Guillain-Barré syndrome:randamised trial.Ann Neurol，2010，67（6）:781-787.
9.van den Berg B，Storm EF，Garssen MJP，et al.Clinical outcome of Guillain-Barré syndrome after prolonged mechanical ventilation.J Neurol Neurosurg Psychiatry，2018，89（9）:949-954.
10.Visser LH，Schmitz PI，Meulstee J，et al.Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange.Dutch Guillain-Barré Study Group.Neurology，1999，53（3）:598-604.
11.Fokkink WR，Walgaard C，Kuitwaard K，et al.Association of Albumin Levels With Outcome in Intravenous Immunoglobulin-Treated Guillain-Barré Syndrome.JAMA Neurol，2017，74（2）:189-196.
12.Wijdicks EF，Klein CJ.Guillain-Barré Syndrome.Mayo Clin Proc，2017；92（3）:467-479.
13.Willison HJ，Jacobs BC，van Doom PA.Guillain-Barré syndrome.Lancet，2016，388（10045）:717-727.
14.Doets AY，Verboon C，van den Berg B，et al.Regional variation of Guillain-Barré syndrome.Brain，2018，141（10）:2866-2877.